Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$1.82 USD
-0.07 (-3.70%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $1.83 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AVTE 1.82 -0.07(-3.70%)
Will AVTE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVTE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVTE
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
AVTE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AVTE
Aerovate Therapeutics to Explore Strategic Alternatives
The 3 Hottest Stock Downgrades From Last Week
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
Biotech Alert: Searches spiking for these stocks today
Aerovate Therapeutics discloses director purchase of $1.55M in common stock